Exactech (NSDQ:EXAC) said today that TPG Capital raised its go-private bid for the orthopedics company by some $108 million, or more than 17%. TPG in October offered $42 per share for the Gainesville, Fla.-based company, for a valuation of about $625 million. Today Exactech said TPG raised the bid 17.3% to $49.25 per share, which would put the […]
Exactech (NSDQ:EXAC) said it inked a definitive merger agreement to be acquired by TPG Capital in a move that will take the company private. Under the deal, TPG Capital will pay approximately $42 per share to acquire all outstanding shares of Gainesville, Fla.-based Exactech, excluding a select number of management stockholders who agreed to exchange a portion […]
Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.
A group of private PE players including the Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts and TPG acquired Biomet for $11.4 billion in 2007, placing medtech veteran Jeffrey Binder at the helm.
Life sciences consulting company Aptiv Solutions announced that it acquired Medical Device Consultants Inc., broadening its reach in medical device regulation and strategy.
North Attleboro, Mass.-based regulatory consulting and clinical research organization MDCI has been around since 1980, offering regulatory and clinical services to the med-tech sector.
Leveraged buyouts, like the $6.3 billion deal to take Kinetic Concepts Inc (NYSE:KCI) private, are as expensive as they’ve been all year, due to ongoing uncertainty about the global economy.
Average monthly interest rates on institutional leveraged loans, the debt used to finance LBOs, rose to 491 basis points more than benchmarks in July, according to Bloomberg News – up from a February low of 378 basis points.
TPG Capital affiliate IVD Holdings Inc. entered into a definitive agreement to acquire all outstanding shares of Immucor Inc.’s (NSDQ:BLUD) common stock in a deal that’s valued at $1.97 billion.
Immucor shareholders will get $27.00 in cash for each share of stock, about 30 percent higher than the stock’s trading price prior to the announcement.
Immucor stock promptly jumped more than 30 percent to $27 per share when the information was released today, inching closer to the stock’s 52-week high of $27.18.